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Abstract
At the end of life, many patients suffer from a syndrome that
simulates classic small bowel obstruction. The traditional approach
to intestinal obstruction is relief of pressure in the gastrointestinal
tract using mechanical methods such as naso-gastric tube insertion
and suctioning. This relieves the distension of the hollow organs and
thus the nausea.. Pharmacologic methods are also used in the care of
these patients, however, there is debate as to which agents to use and
when to use them.

The Medical Decompression protocol is a non-invasive
pharmacologic approach to this problem. It brings with it ease and
economy of delivery, the ability to administer it in intravenous as
well as oral form, and is a multi-agent protocol of tried and true
drugs used at the end of life: 1/2 Metoclopramide, Dexamethasone,
Diphenhydramine, and Pantoprazole
Prior to initiating this intervention, patients and their families
are educated and are aware that this intervention is most likely a
temporary measure aimed at symptom relief, as well as an attempt to
improve quality of life.
Our sample contained 42 males and 62 females, with an average
age of about 70 years. About 51% of participants received MD (n = 53).
Results indicated that there was a statistically significant difference
between the two groups related to days to progress diet.

We propose that a pharmacologic method such as MD is strongly
considered as first line treatments for the functional intestinal
obstruction syndrome and indeed be considered as adjuncts to allow
the removal of invasive mechanical interventions in the end of life
patient.

Introduction
Many patients with advanced cancer suffer from a condition
that simulates classic small bowel obstruction. This often
described but little studied para neoplastic syndrome goes by
many names, (e.g.; Pseudo-Intestinal Obstruction, Ogilvie’s
Symbiosis Group
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Syndrome) and manifests as abdominal pain, intractable nausea
and unremitting vomiting. We use the term Functional Intestinal
Obstruction (FIO) to describe this constellation of symptoms.

In a review of the literature, using data from the United States
Department of Health and Human Services, it is estimated that
in the United States approximately 62,000 patients are treated
annually, in-hospital, for Functional Intestinal Obstruction with
an average length of stay of 6 days [1]. Based on an average cost
per hospital day of $1800.00 this problem becomes a significant
one in terms of the total burden on the health care system costing
upwards of $669 million a year [2].
For the individual patient and their family however, the
premature loss of activity due to the debility of chronic nausea
and vomiting prior to the patient’s death is devastating, both in
physical and emotional terms.

Traditional therapies include Nasogastric Tube (NGT)
suctioning to relieve intraluminal pressure and volume upstream
of the functional obstruction. Studies however, have shown that
NGT placement with subsequent suctioning fails to relieve the
symptoms of FIO in more than 86% of cases [3].
To alleviate the discomfort and potential side effects of NGT
placements (i.e.: sinusitis, nasal irritation with epistaxis and
nasal cartilage erosion, pain, increased incidence of aspiration
pneumonia) Percutaneously Inserted Endoscopically Placed
Gastrostomy (PEG) tubes have been used with varying degrees
of success to alleviate the pressure and subsequent nausea
associated with FIO.
Although successful in 83%-96% of patients in alleviating
the nausea of FIO, PEG tubes cannot be placed in many cases [3].
This procedure also introduces additional cost, approximately
$9600.00 for insertion of PEG between practitioner and
institutional charges and the social and psychological burden
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placed on the patient and family [4,5].Surgical Interventions
are the sine qua non for relief of Intestinal Obstruction both
Functional and Mechanical, however these procedures are
indicated when patients have relatively good functional status, an
expected lifespan of greater than 2 months and with a defined
area of obstruction that can be relieved by diversion of the
enteral stream [3]. Cost for surgical intervention ranges from
$27,000 to $57,000 per procedure, not including the costs of any
post-operative complications and ongoing supplies [3].Medical
therapies have centered on the use of pro-motility, anti-secretory,
and anti cholinergic agents to medically reduce the intraluminal
pressure by reducing the production of intestinal secretions and
to assist intestinal peristalsis [6].
While the syndrome of chronic pseudo-obstruction has been
described in the literature, the full impact of the problem has
not been outlined. For example, Laval, Arvieux, Stefani, Villard,
Mestralet and Cadin placed FIO patients in a 3 tiered system
with medications stratified [7]. The authors made a case for an
organized strategy for this problem but did not introduce any
new techniques.

Several authors have focused on the use of Octreotide, an inject
able medication, along with corticosteroids and anti-emetics
for relief of symptoms of FIO [8,9]. These reports regarding the
effectiveness of various regimens including Octreotide had 15, 1,
and 4 subjects respectively. Additionally, Octreotide is an inject
able medication that is not outpatient friendly. The literature
reveals no studies that investigate the effectiveness of our MD
Regimen.

The purpose of this study was to examine the effect of the
MD protocol.MD consists of 1/2 Metoclopramide (Reglan™, Teva,
USA Pharmaceuticals) 10mg IVP every six hours, Dexamethasone
(Decadron™, Westword, USA) 4mg IVP every six hours,
Diphenhydramine (Bendryl™, APP Pharmaceuticals) 25mg every
eight hours, and Pantoprazole (Protonix™, Novaplus, USA) 40mg
IV daily.

Method

Participants
There were 42 males (about 40%of the sample) and 62
females (roughly 60% of the sample), with a mean age of 70
years (SD = 13.69), ranging from 35 years to 97 years of age. The
sample size in each group were equivalent, as 51% of participants
received MD (
), and 49% of participants did not receive MD
(n = 51), for a total sample size of 104 participants. The majority
of participants (about 70%, n = 73) had an NG tube previously,
while just under 30% of the sample (n = 31) did not.
Of those participants following a medically directed prior to
admission (22%of the sample, n = 23) most had a clear liquid
diet. Please see table 1 [Table 1].

Prior to admission, the majority of participants had NG tubes,
reported nausea and vomiting, and were antiemetic. Please see
table 2 [Table 2].

There were 10 primary cancer diagnoses for all patients (n =
104). Please see table 3 [Table 3].

Table 1: Pre-admission diet
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Diet

n

%

Clear liquid

13

12.5

4

3.8

Soft

6

Regular
n= 23

Table 2: preadmission status

5.8

Status

No

Yes

NG

29.8% (31)

70.28% (73)

Nausea
Vomit
Antiemetic

3.8%(4)

96.28% (100)

15.4%(16)

84.68% (88)

11.5% (12)

Notes: Number in parentheses indicates n.

88.58% (92)

NG= Nasogastric Tube

Table 3: Cancer diagnoses
Type

n

%

bladder

2

1.9

46

44.2

7

6.7

23

22.1

1

1

breast
colon
kidney
liver
lung
ovary
pancreas
stomach
uterus

2
1
9
6
7

1.9
1

8.7
5.8
6.7

The most common comorbidity was multiple conditions (n =
38, about 37%of the sample). For singular or no comorbidities,
the most common were as follows: cardiac (n = 32, 31%of the
sample), no comorbidity (n = 25, 24%of the sample), and then
pulmonary, neuromuscular, or diabetes (all n = 3, about 3%of the
sample).

Procedure

Medical records were deemed eligible if patients were: aged
18 years, had a diagnosis of functional bowel obstruction, had
documented abdominal pain, intractable nausea &/or vomiting,
and advanced stage GI or reproductive tract cancer. Records were
excluded if for complete intestinal obstruction on radiological
examination. Eligible cases prior to April 2007 (no MD, which
was first implemented in April 2007) and charts dated after April
2007 (received the MD regimen) were compared using t-tests on
the outcome variable days to advance diet.
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Results
A mean of 0.08 doses (SD = .56) were required to resolve
symptoms. It took a mean of 4.6 days to advance diet (SD = 3.84).

A t-test was conducted to investigate significant differences
in means between the two group. Results indicated that there
was a statistically significant difference between the medical
decompression group (M = 1.30, SD = .93) and the non-medical
decompression group (M = 4.60, SD = 3.84) related to days to
progress diet t(54.43)= 5.91, p= <.01.
To ensure the two groups were equivalent, and to allow
for more robust causal inference, propensity score matching
estimates were utilized. Please see figure 1[Figure 1].
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This decrease of 1.3 days in time to the improvement of patient
symptoms leading to advancement of diet represents an increase
in patient and family satisfaction, decrease in acute care length of
stay and, additional cost savings to the system due to a decreased
need for surgical intervention in this patient population.
No studies have been found in the literature that addresses
this symptom complex with this simple and relatively inexpensive
regime. We believe that additional studies should be conducted to
investigate not merely the effectiveness of the MD protocol, but
the potential cost savings to the Health Care System and effect on
patient and family satisfaction at the end of life.
If these studies replicate our findings, and the suffering caused
by these frequent sequelae of terminal illness can be relieved, MD
could be added to the list of “Gold” standards for Palliative Care
therapies.
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